Mireca Medicines GmbH (Mireca) is a Tübingen based pre-clinical stage bio-pharmaceutical company focusing on research and development of treatments for rare, neuro-degenerative eye diseases. Mireca was set up with the aim to translate research data generated in the EU-funded DRUGSFORD project (www.drugsford.eu) into treatments for patients, with all original consortium partners as shareholders. Thus providing access to a network of experienced scientists and entrepreneurs, all relevant intellectual property and a GMP-compliant manufacturing process. The lead compound LP-DF003 is a small molecule capable of down regulating over expressed cGMP in inherited retina degeneration, covering a broad amount of underlying gene mutations. Mireca will first develop LP-DF003 for Retinitis Pigmentosa for which the EMA Orphan Drug Status (ODD) was granted and no other treatment option is currently available.